Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:623673.
doi: 10.1155/2011/623673. Epub 2011 Apr 10.

An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost

Geoffrey Teehan  1 , Robert L Benz
Affiliations

An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost

Geoffrey Teehan et al. Anemia. 2011.

Abstract

Background. Erythropoietin deficiency and anemia occur in Chronic Kidney Disease (CKD) and may be treated with Erythropoietin Stimulating Agents (ESAs). The optimal hemoglobin, in non-End Stage Renal Disease CKD, is controversial. Methods. We review three recent randomized trials in anemia in CKD: CHOIR, CREATE, and TREAT. Results. CHOIR (N = 1432) was terminated early with more frequent death and cardiovascular outcomes in the higher Hb group (HR 1.34: 95% C.I. 1.03-1.74, P = .03). CREATE (N = 603) showed no difference in primary cardiovascular endpoints. Stroke was more common in the higher Hb group (HR 1.92; 95% C.I. 1.38-2.68; P < .001) in TREAT (N = 4038). Conclusions. There is no benefit to an Hb outside the 10-12 g/dL range in this population. To avoid transfusions and improve Quality of Life, ESAs should be used cautiously, especially in patients with Diabetes, CKD, risk factors for stroke, and ESA resistance.

PubMed Disclaimer

References

    1. World Health Organization. Nutritional Anaemias: Report of a WHO scientific group. 1968;(Tech. Rep. 405: 5–37) - PubMed
    1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia. The Third National Health and Nutrition Examination Survey (1988–1994) Archives of Internal Medicine. 2002;162(12):1401–1408. - PubMed
    1. Obrador GT, Roberts T, St. Peter W.L. WL, Frazier E, Pereira BJG, Collins AJ. Trends in anemia at initiation of dialysis in the United States. Kidney International. 2001;60(5):1875–1884. - PubMed
    1. Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (the SLEEPO study) American Journal of Kidney Diseases. 1999;34(6):1089–1095. - PubMed
    1. Teehan BP, Krantz S, Stone WA, et al. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. American Journal of Kidney Diseases. 1991;18(1):50–59. - PubMed

LinkOut - more resources